Chemotherapy prescribing trends for gastric cancer vary significantly based on geographic region.
By Dustin Phan, Analyst
13 April 2016
I am an analyst at Datamonitor Healthcare based in the San Diego – California office, where I am currently a member of...
Read full bio
The most commonly used chemotherapeutic regimens for advanced and metastatic gastric cancer vary significantly across geographic regions. Datamonitor Healthcare surveyed 227 oncologists and gastroenterologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to calculate the gastric cancer treatment population and to gain an understanding of current and future prescribing patterns in gastric cancer. For Stage IV gastric cancer, triplet regimens containing cisplatin such as ECF (epirubicin, cisplatin, and fluorouracil) and DCF (docetaxel, cisplatin, and fluorouracil) are among the most popular regimens in the US and EU markets, while TS-1 (gimeracil/oteracil potassium/tegafur; Otsuka/Nordic Group) plus cisplatin is the most commonly used regimen in Japan. Patients unable to tolerate three-drug regimens will typically be administered a doublet regimen containing a fluoropyrimidine such as capecitabine or fluorouracil combined with a platinum-based therapy.
Figure: Top three regimens used in the first-line treatment of Stage IV gastric cancer patients, by country
Source: Datamonitor Healthcare’s proprietary gastric cancer survey, December 2015
This is excerpted from Datamonitor Healthcare’s Gastric Cancer: Treatment, exploring how gastric cancer patients are currently managed, and taking a detailed look at current treatment algorithms and future prescribing trends.
Get your free demo today – simply fill in the form to the right.